{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:28:27Z","timestamp":1787164107107,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale Delle Ricerche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncogenic KRAS mutations drive tumorigenesis by promoting pro-survival signaling and metabolic reprogramming, including the maintenance of redox balance to evade oxidative stress. A key mechanism involves the upregulation of the xCT cystine\/glutamate antiporter, which sustains glutathione (GSH) synthesis and protects cells from oxidative damage and ferroptosis. While it is known that the ETS1-ATF4 complex mediates transcriptional upregulation of xCT, the upstream regulators linking KRAS signaling to this axis remain to be fully defined. Here, we demonstrate that oncogenic KRAS signaling induces the GSK3\u03b2-mediated proteasomal degradation of the tumor suppressor CCDC6. We show that CCDC6 acts as a negative regulator of the xCT-promoting transcription factor ATF4 by directly interacting with it and preventing its recruitment to the xCT promoter. Consequently, KRAS-driven CCDC6 degradation disinhibits ATF4, leading to increased xCT expression, elevated intracellular GSH, and enhanced resistance to ferroptosis. Crucially, pharmacological inhibition of CCDC6 turnover using proteasome, GSK3\u03b2, or specific KRAS mutant inhibitors (Sotorasib, Adagrasib, HRS4642) restored CCDC6 protein levels and robustly sensitized KRAS-mutated cells to ferroptosis-inducing agents like Sulfasalazine. Furthermore, validation in preclinical models and human colorectal cancer samples revealed that CCDC6 protein levels are predominantly downregulated in KRAS-mutant cases. This work uncovers a novel KRAS\/CCDC6\/xCT signaling axis that mediates ferroptosis resistance in KRAS-mutated cancers. Moreover, it identifies CCDC6 turnover as a critical vulnerability and a promising therapeutic target to enhance the efficacy of ferroptosis-inducing agents.<\/jats:p>","DOI":"10.1007\/s10495-026-02400-4","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:00:03Z","timestamp":1784048403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion"],"prefix":"10.1007","volume":"31","author":[{"given":"Daniela","family":"Criscuolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Baviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vigliar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsei","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorina","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Troncone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Marina","family":"Melillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Celetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2400_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar J, Kashofer K (2020) Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev 39:1029\u20131038","journal-title":"Cancer Metastasis Rev"},{"key":"2400_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"APG Consortium","year":"2017","unstructured":"Consortium APG (2017) AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov 7:818\u2013831","journal-title":"Cancer Discov"},{"key":"2400_CR3","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"15","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL (2020) The frequency of Ras mutations in cancer. Cancer Res 15:2969\u20132974","journal-title":"Cancer Res"},{"key":"2400_CR4","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","volume":"12","author":"JH Cook","year":"2021","unstructured":"Cook JH, Melloni GEM, Gulhan DC, Park PJ, Haigis KM (2021) The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun 12:1808","journal-title":"Nat Commun"},{"key":"2400_CR5","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1038\/s41467-019-11530-0","volume":"10","author":"IG Serebriiskii","year":"2019","unstructured":"Serebriiskii IG et al (2019) Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun 10:3722","journal-title":"Nat Commun"},{"key":"2400_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2019.06.007","volume":"59","author":"AK Murugan","year":"2019","unstructured":"Murugan AK, Grieco M, Tsuchida N (2019) RAS mutations in human cancers: roles in precision medicine. Semin Cancer Biol 59:23\u201335","journal-title":"Semin Cancer Biol"},{"key":"2400_CR7","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.ccell.2025.05.016","volume":"43","author":"LJ Stanland","year":"2025","unstructured":"Stanland LJ et al (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. Cancer Cell 43:1815\u20131832","journal-title":"Cancer Cell"},{"key":"2400_CR8","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ccell.2025.07.006","volume":"43","author":"J Feng","year":"2025","unstructured":"Feng J et al (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer Cell 43:1866\u20131884","journal-title":"Cancer Cell"},{"key":"2400_CR9","doi-asserted-by":"publisher","first-page":"1654814","DOI":"10.1080\/23723556.2019.1654814","volume":"7","author":"JKM Lim","year":"2019","unstructured":"Lim JKM, Leprivier G, Sorensen PH (2019) RAS-driven oncogenesis is supported by downstream antioxidant programs. Mol Cell Oncol 7:1654814","journal-title":"Mol Cell Oncol"},{"key":"2400_CR10","doi-asserted-by":"publisher","first-page":"9433","DOI":"10.1073\/pnas.1821323116","volume":"116","author":"JKM Lim","year":"2019","unstructured":"Lim JKM et al (2019) Cystine\/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A 116:9433\u20139442","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2400_CR11","doi-asserted-by":"publisher","first-page":"e08399","DOI":"10.1016\/j.heliyon.2021.e08399","volume":"7","author":"F Morra","year":"2021","unstructured":"Morra F et al (2021) The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis. Heliyon 7:e08399","journal-title":"Heliyon"},{"key":"2400_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.37349\/etat.2022.00101","volume":"3","author":"D Criscuolo","year":"2022","unstructured":"Criscuolo D, Morra F, Celetti A (2022) A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options. Explor Target Antitumor Ther 3:570\u2013581","journal-title":"Explor Target Antitumor Ther"},{"key":"2400_CR13","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/ijc.31106","volume":"142","author":"A Cerrato","year":"2018","unstructured":"Cerrato A, Merolla F, Morra F, Celetti A (2018) CCDC6: the identity of a protein known to be partner in fusion. Int J Cancer 142:1300\u20131308","journal-title":"Int J Cancer"},{"key":"2400_CR14","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1038\/onc.2011.90","volume":"30","author":"JS Zhang","year":"2011","unstructured":"Zhang JS et al (2011) Mutant K-Ras increases GSK-3\u03b2 gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. Oncogene 30:3705\u20133715","journal-title":"Oncogene"},{"key":"2400_CR15","doi-asserted-by":"publisher","first-page":"12697","DOI":"10.18632\/oncotarget.3708","volume":"6","author":"F Morra","year":"2015","unstructured":"Morra F et al (2015) FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. Oncotarget 6:12697\u201312709","journal-title":"Oncotarget"},{"key":"2400_CR16","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41467-021-26871-y","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J et al (2021) Genetic fusions favor tumorigenesis through degron loss in oncogenes. Nat Commun 12:6704\u20136718","journal-title":"Nat Commun"},{"key":"2400_CR17","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1038\/onc.2010.179","volume":"29","author":"V Leone","year":"2010","unstructured":"Leone V et al (2010) CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1. Oncogene 29:4341\u20134351","journal-title":"Oncogene"},{"key":"2400_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41586-020-2188-x","volume":"580","author":"K Luck","year":"2020","unstructured":"Luck K et al (2020) A reference map of the human binary protein interactome. Nature 580:402\u2013408","journal-title":"Nature"},{"key":"2400_CR19","doi-asserted-by":"publisher","first-page":"e49298","DOI":"10.1371\/journal.pone.0049298","volume":"7","author":"C Luise","year":"2012","unstructured":"Luise C et al (2012) Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity. PLoS ONE 7:e49298","journal-title":"PLoS ONE"},{"key":"2400_CR20","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K et al (2016) The integrated stress response. EMBO Rep 17:1374\u20131395","journal-title":"EMBO Rep"},{"key":"2400_CR21","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1038\/onc.2017.146","volume":"36","author":"D Chen","year":"2017","unstructured":"Chen D et al (2017) ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner. Oncogene 36:5593\u20135608","journal-title":"Oncogene"},{"key":"2400_CR22","doi-asserted-by":"publisher","first-page":"123125","DOI":"10.1016\/j.lfs.2024.123125","volume":"358","author":"O Sogbein","year":"2024","unstructured":"Sogbein O et al (2024) Bortezomib in cancer therapy: mechanisms, side effects, and future proteasome inhibitors. Life Sci 358:123125. https:\/\/doi.org\/10.1016\/j.lfs.2024.123125","journal-title":"Life Sci"},{"key":"2400_CR23","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","volume":"15","author":"PW Gout","year":"2001","unstructured":"Gout PW, Buckley AR, Simms CR, Bruchovsky N, Sulfasalazine (2001) a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15:1633\u20131640","journal-title":"Leukemia"},{"key":"2400_CR24","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM (2024) Targeting KRAS in cancer. Nat Med 30:969\u2013983","journal-title":"Nat Med"},{"key":"2400_CR25","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou C et al (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell 42:1286\u20131300","journal-title":"Cancer Cell"},{"key":"2400_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/cells9040952","volume":"9","author":"A Resovi","year":"2020","unstructured":"Resovi A et al (2020) CCN-based therapeutic peptides modify pancreatic ductal adenocarcinoma microenvironment and decrease tumor growth in combination with chemotherapy. Cells 9:952\u2013965","journal-title":"Cells"},{"key":"2400_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/1878-0261.13816","volume":"19","author":"A Anastasia","year":"2025","unstructured":"Anastasia A et al (2025) Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient-derived xenograft models. Mol Oncol 19:1075\u20131091","journal-title":"Mol Oncol"},{"key":"2400_CR28","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1126\/science.aav6703","volume":"363","author":"TG Bivona","year":"2019","unstructured":"Bivona TG (2019) Dampening oncogenic RAS signaling. Science 363:1280\u20131281","journal-title":"Science"},{"key":"2400_CR29","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/ijc.70345","volume":"158","author":"G Wei","year":"2026","unstructured":"Wei G et al (2026) The multiple roles of the disordered protein CCDC6 in cancer development. Int J Cancer 158:2520\u20132529","journal-title":"Int J Cancer"},{"key":"2400_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamaoncol.2015.6065","volume":"2","author":"JF Seligmann","year":"2016","unstructured":"Seligmann JF et al (2016) Combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with RAS wild-type advanced colorectal cancer. JAMA Oncol 2:633\u2013642","journal-title":"JAMA Oncol"},{"key":"2400_CR31","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1158\/0008-5472.CAN-25-0073","volume":"85","author":"D Conticelli","year":"2025","unstructured":"Conticelli D et al (2025) AREG and EREG are predictive biomarkers of response to EGFR inhibition in gastroesophageal cancer. Cancer Res 85:3111\u20133122","journal-title":"Cancer Res"},{"key":"2400_CR32","doi-asserted-by":"publisher","first-page":"15628","DOI":"10.18632\/oncotarget.3858","volume":"6","author":"V Leone","year":"2015","unstructured":"Leone V et al (2015) Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity. Oncotarget 6:15628\u201315638","journal-title":"Oncotarget"},{"key":"2400_CR33","doi-asserted-by":"crossref","unstructured":"Chen J, Lin S, Liu C (2014) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev CD004800","DOI":"10.1002\/14651858.CD004800.pub3"},{"key":"2400_CR34","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P et al (2017) QuPath: Open-source software for digital pathology image analysis. Sci Rep 7:16878","journal-title":"Sci Rep"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02400-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:02:32Z","timestamp":1787162552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02400-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2400"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02400-4","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Confllict of interest\n                      .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"194"}}